Asset price forecast: consolidation or breakout? GSK holds firm near GBX 1,779.50

Traders Union
All News
Financial News
GSK slips 0.48% to GBX 1,779.50

Highlights

GSK plc trades at GBX 1,779.50, significantly above its MA-20, MA-50, and MA-200 levels, confirming a robust bullish structure across all timeframes.
GSK expanded its share buyback program with new purchases totaling 345,000 shares, pushing treasury shares above 255 million, and reported robust statutory profits supported by milestone payments to AnaptysBio.
Short-term oscillators show overbought conditions despite bullish momentum, with GSK's expected five-day range at GBX 1,745–1,878.50 and an 80 percent probability of further upside.

Share buybacks and profit growth strengthen sentiment amid steady votes

GSK recently expanded its share buyback program, acquiring 170,000 and 175,000 ordinary shares in separate transactions through BNP Paribas SA and raising its total treasury shares above 255 million. The ongoing buybacks follow cumulative purchases of over 7.6 million shares since September 2025, while the company's overall voting rights remain unchanged at 4,060,139,755. GSK also reported robust statutory profits and healthy earnings, with additional milestone payments made to AnaptysBio contributing to positive results for both firms.

Overbought signals contrast with firm momentum as volatility rises

Momentum indicators on the daily timeframe reflect ongoing buyer control, as seen in the bullish MACD and firm ADX. However, oscillators like RSI, Stoch RSI, CCI, and BBP all signal overbought conditions, suggesting some caution is warranted in the short term. The Awesome Oscillator remains supportive of the prevailing upward move. On the day, GSK is down GBX 8.50 or 0.48%, with no notable gap between yesterday’s close and today’s open. The price currently sits in the lower half of the session’s range, signaling moderate intraday volatility and mild pressure following the open. There is a clear divergence between the strong underlying trend and stretched intraday oscillators, hinting at possible near-term consolidation or pause.

Upside favored as technical strength limits pullback risk

Looking ahead, the expected price range for GSK over the next five trading days is GBX 1,745 to GBX 1,878.50. Based on weekly readings (RSI, MACD, ADX, and MA-50), the probability of further price increase is very high (more than 80%), while a decline is less likely. The baseline scenario envisions sideways movement between established support and resistance. Under a bullish scenario, a breakout above the upper end of the range could fuel a test of GBX 1,878.50 or higher, while breakdown below GBX 1,745 support would open the path to a deeper pullback, though current trend signals make this outcome less likely for now.

Anton Kharitonov, expert at Traders Union, notes that while GSK’s technical structure is clearly bullish across multiple timeframes, overstretched oscillators and minor intraday weakness signal the potential for near-term consolidation. He sees the ongoing share buybacks and robust earnings as supportive, but urges caution given the persistent overbought readings. Overall, Kharitonov remains defensively positioned, waiting for clearer signals before committing. "Until GBX 1,745 is broken or overbought conditions unwind, I see little justification for chasing upside here — base case remains neutral within the current range."

Previously it was noted that buyback activity and investor accumulation were offset by R&D pipeline risks in a period of low volatility and cautious sentiment. Technical analysis showed persistent bullish signals, with oscillators highlighting both overbought momentum and the need for caution amid mixed indicator readings.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.